Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Beyond Air Inc XAIR

Healthcare Medical Devices
Beyond Air, Inc. is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received United States Food and Drug Administration (FDA) approval for its first system, LungFit PH, for... see more

Recent & Breaking News (NDAQ:XAIR)

Beyond Cancer(TM) to Present Pre-Clinical Data for Ultra-High Concentration Nitric Oxide Therapy at the 2022 SITC Annual Meeting

GlobeNewswire October 5, 2022

Beyond Air® Announces that Annals of the American Thoracic Society Published a Review of the Third Pilot Study of High Dose Nitric Oxide for Bronchiolitis

GlobeNewswire October 3, 2022

Beyond Air® To Participate in Three Upcoming Investor Conferences

GlobeNewswire September 16, 2022

Beyond Air® Affiliate Beyond Cancer(TM) Doses Initial Patient in First-in-Human Phase 1 Study of Ultra-High Concentration Nitric Oxide Therapy at Tel Aviv Sourasky Medical Center (Ichilov)

GlobeNewswire August 23, 2022

Beyond Air® Reports Financial Results for the First Quarter of Fiscal Year 2023

GlobeNewswire August 11, 2022

Beyond Air® Schedules First Fiscal Quarter 2023 Financial Results Conference Call and Webcast

GlobeNewswire July 27, 2022

Beyond Air® Reports Financial Results for Fourth Fiscal Quarter and Year-End 2022

GlobeNewswire June 28, 2022

Beyond Air's LungFit® PH Receives FDA Approval to Treat Term and Near-Term Neonates with Hypoxic Respiratory Failure

GlobeNewswire June 28, 2022

Beyond Air® Announces Fiscal Year End 2022 Financial Results Conference Call and Webcast Moved to Tuesday, June 28th

GlobeNewswire June 14, 2022

Beyond Cancer(TM) Announces the Appointment of Jedidiah Monson, M.D. to Chief Medical Officer

GlobeNewswire June 1, 2022

Beyond Air® Presents Positive Study Update from the At-Home LungFit® GO Pilot Study for Nontuberculous Mycobacterial Lung Disease at the American Thoracic Society International Conference 2022

GlobeNewswire May 17, 2022

Beyond Cancer, Ltd. Appoints Susan Howell Jones, CPA as Chief Financial Officer

GlobeNewswire May 17, 2022

Beyond Air® Schedules Fiscal Year 2022 Financial Results Conference Call and Webcast

GlobeNewswire May 16, 2022

Beyond Air® Reports Positive Long-Term Safety Data for High Concentration Inhaled Nitric Oxide in Bronchiolitis at the Pediatric Academic Societies Meeting 2022

GlobeNewswire April 25, 2022

Beyond Air® Presents Positive Safety and Efficacy Data for Inhaled Nitric Oxide to Treat COVID-19 at ECCMID 2022

GlobeNewswire April 25, 2022

Beyond Air® to Participate in Three Upcoming Medical Conferences

GlobeNewswire April 18, 2022

Beyond Cancer(TM) Announces New Preclinical Data Presented at American Association for Cancer Research (AACR) Showing Ultra-High Concentration Nitric Oxide Therapy Anti-Tumor Effect

GlobeNewswire April 11, 2022

Beyond Cancer(TM) to Present Two Abstracts for Ultra-High Concentration Nitric Oxide Therapy at the 2022 AACR Annual Meeting

GlobeNewswire March 8, 2022

Beyond Air® Reports Financial Results for the Third Quarter of Fiscal Year 2022

GlobeNewswire February 10, 2022

Beyond Air® Announces Participation at Upcoming Investor Conferences in March 2022

GlobeNewswire February 8, 2022